Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)--a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen. (Q33676764)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)--a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19717534%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)--a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19717534%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

based on heuristic

inferred from title

author name string

G Bertelli

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19717534%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

E Ireland

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19717534%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

C F Snowdon

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19717534%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

K Drosik

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19717534%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

H Karnicka-Mlodkowska

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19717534%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

R C Coombes

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19717534%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

J M Bliss

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19717534%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

publication date

28 August 2009

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19717534%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Annals of Oncology

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19717534%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

21

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19717534%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19717534%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

498-505

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19717534%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2826098

21 June 2018

Tamoxifen and endometrial cancer. Is screening necessary? A review of the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2826098

21 June 2018

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2826098

21 June 2018

The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: baseline endometrial sub-protocol data on the effectiveness of transvaginal ultrasonography and diagnostic hysteroscopy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2826098

21 June 2018

Endometrial pathologies associated with postmenopausal tamoxifen treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2826098

21 June 2018

Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2826098

21 June 2018

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2826098

30 October 2018

Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2826098

30 October 2018

Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2826098

30 October 2018

Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2826098

30 October 2018

Endometrial thickness of postmenopausal breast cancer patients treated with tamoxifen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2826098

30 October 2018

Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2826098

30 October 2018

Modification of ultrasonographically measured endometrial thickness after discontinuation of adjuvant therapy with tamoxifen in postmenopausal breast cancer patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2826098

30 October 2018

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2826098

30 October 2018

Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2826098

30 October 2018

Surveillance for uterine abnormalities in tamoxifen-treated breast carcinoma survivors: a community based study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2826098

30 October 2018

Diagnostic pitfalls of ultrasonographic uterine screening in women treated with tamoxifen.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2826098

30 October 2018

Endometrial changes with tamoxifen: comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19717534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen

1 reference

https://pubmed.ncbi.nlm.nih.gov/19717534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Should tamoxifen users be screened for endometrial lesions?

1 reference

https://pubmed.ncbi.nlm.nih.gov/19717534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tamoxifen and the endometrium: findings of pelvic ultrasound examination

1 reference

https://pubmed.ncbi.nlm.nih.gov/19717534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19717534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Transvaginal endometrial sonography in postmenopausal women taking tamoxifen

1 reference

https://pubmed.ncbi.nlm.nih.gov/19717534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Discrepancy between ultrasonography and hysteroscopy and histology of endometrium in postmenopausal breast cancer patients using tamoxifen

1 reference

https://pubmed.ncbi.nlm.nih.gov/19717534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening

1 reference

https://pubmed.ncbi.nlm.nih.gov/19717534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ultrasonographic measurement of endometrial changes following discontinuation of tamoxifen treatment in postmenopausal breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19717534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Uterine surveillance of asymptomatic postmenopausal women taking tamoxifen

1 reference

https://pubmed.ncbi.nlm.nih.gov/19717534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thickened endometrium caused by tamoxifen returns to normal following tamoxifen cessation

1 reference

https://pubmed.ncbi.nlm.nih.gov/19717534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pretreatment and prospective assessment of endometrium in menopausal women taking tamoxifen for breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19717534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ACOG committee opinion. No. 336: Tamoxifen and uterine cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19717534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prospective endometrial assessment of breast cancer patients treated with third generation aromatase inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/19717534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Aromatase inhibitors reverse tamoxifen induced endometrial ultrasonographic changes in postmenopausal breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19717534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

1 reference

https://pubmed.ncbi.nlm.nih.gov/19717534

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/ANNONC/MDP358

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19717534%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19717534%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19717534%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33676764&oldid=1988448873"